within Pharmacolibrary.Drugs.ATC.N;

model N05CF02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 4.666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00054,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05CF02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Zolpidem is a non-benzodiazepine hypnotic agent of the imidazopyridine class primarily used for the short-term treatment of insomnia. It works by enhancing the activity of gamma-aminobutyric acid (GABA) via selective agonism at the benzodiazepine-1 (omega-1) receptor subtype. Zolpidem is approved and widely used today for sleep disorders.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported in healthy adult volunteers (both sexes), typically aged 18-45 years, under fasting conditions after single oral dose.</p><h4>References</h4><ol><li><p>Feng, X, et al., &amp; Shen, M (2019). Zolpidem and zolpidem phenyl-4-carboxylic acid pharmacokinetics in oral fluid after a single dose. <i>Drug testing and analysis</i> 11(7) 1076–1082. DOI:<a href=\"https://doi.org/10.1002/dta.2594\">10.1002/dta.2594</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30912258/\">https://pubmed.ncbi.nlm.nih.gov/30912258</a></p></li><li><p>Giorgi, M, et al., &amp; Briganti, A (2012). Pharmacokinetics and pharmacodynamics of zolpidem after oral administration of a single dose in dogs. <i>American journal of veterinary research</i> 73(10) 1650–1656. DOI:<a href=\"https://doi.org/10.2460/ajvr.73.10.1650\">10.2460/ajvr.73.10.1650</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23013193/\">https://pubmed.ncbi.nlm.nih.gov/23013193</a></p></li><li><p>Byeon, JY, et al., &amp; Lee, YJ (2018). The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem. <i>Archives of pharmacal research</i> 41(9) 931–936. DOI:<a href=\"https://doi.org/10.1007/s12272-018-1070-y\">10.1007/s12272-018-1070-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30178440/\">https://pubmed.ncbi.nlm.nih.gov/30178440</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05CF02;
